Indy Hematology Review
Avatar

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk Stratification and Treatment

By Indy Hematology Review FEATURING Ayalew Tefferi
By Indy Hematology Review FEATURING Ayalew Tefferi
765 views
April 18, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Related Content

AUTOPLAY
24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

06:18
Cleveland Clinic Taussig Cancer Institute

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Feat. A. Gerds
21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
18:42
Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

Feat. A. Goldberg
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
24:48
Indy Hematology Review

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Feat. R. Rampal
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
08:11
Krisstina Gowin

Counseling Patients With Newly Diagnosed PV or ET

17:23
Vanderbilt University Medical Center (VUMC)

Management of MF After Ruxolitinib Failure

Feat. A. Kishtagari
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
13:38
Insights from 2024 EHA Annual Meeting

Top 5 Impactful MPN Abstracts From Summer Conferences

Feat. P. Bose
11:03
Moffitt Cancer Center

Current Treatment Landscape of JAK Inhibitors in MF

Feat. A. Kuykendall
29:17
UChicago Medicine

Overview of Recent Updates in MPNs and MDS

Feat. S. Kosuri